Fosun Pharma clinical trials

Also known as Henlius.

Part of Shanghai Fosun High Technology (Group) Co., Ltd., which holds 36.00% as of 2025-12-31. Source

The registry lists 194 studies whose lead sponsor is Fosun Pharma or one of 11 companies grouped under it. 81 are recruiting or about to start. Per ClinicalTrials.gov, last updated Oct 22, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 194. Browse all 194 →

• A Phase II Study of FXR0906 in Patients With Severe Hypertriglyceridemia or Hypertriglyceridemia With ASCVD.Not yet recruitingNCT07889245Phase 2

  Sponsor listed in the registry: Fosun Pharmaceutical Industrial Development (Shenzhen) Co., Ltd.

• Pharmacokinetic Characteristics, Safety, and Immunogenicity of HLX29 Compared With HLX11Not yet recruitingNCT07776132Phase 1

  Sponsor listed in the registry: Shanghai Henlius Biotech

• A Phase II Clinical Trial to Evaluate the Efficacy and Safety of FXS5626 in Patients With NIURecruitingNCT07552012Phase 2

  Sponsor listed in the registry: Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.

• Phase I Study of FXS0683 in the Treatment of Blood TumorsRecruitingNCT07616089Phase 1

  Sponsor listed in the registry: Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.

• QT Interval Effects Study of Oral FXS5626 TabletsRecruitingNCT07695779Phase 1

  Sponsor listed in the registry: Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.

• A Phase I Study to Evaluate the Safety, Tolerability, and PK of HLX43 in Advanced/Metastatic Solid TumorsEnrolling by invitationNCT06115642Phase 1

  Sponsor listed in the registry: Shanghai Henlius Biotech

• Mass Balance Study of [¹⁴C]FXS4640 in Healthy Adult MalesNot yet recruitingNCT07872579Phase 1

  Sponsor listed in the registry: Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.

• A Study to Learn the Safety and Efficacy of HLX37 in Combination With Chemotherapy for First-line Treatment in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung CancerNot yet recruitingNCT07865910Phase 2/3

  Sponsor listed in the registry: Shanghai Henlius Biotech

• A Phase II Clinical Study to Evaluate HLX43 in Subjects With Advanced Non-small Cell Lung Cancer (NSCLC)RecruitingNCT06907615Phase 2

  Sponsor listed in the registry: Shanghai Henlius Biotech

• A Study of XS-04 in Patients With Relapsed or Refractory Hematologic MalignanciesRecruitingNCT06820268Phase 1

  Sponsor listed in the registry: Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.

• XS-03 in Combination With FOLFOX or FOLFIRI and Bevacizumab for Treatment of Metastatic Colorectal Cancer Patients With RAS MutationEnrolling by invitationNCT06936527Phase 1/2

  Sponsor listed in the registry: Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.

• A Multicenter, Open-label Study Evaluating the Long-term Safety and Efficacy of XH-S003 Capsules in Patients With Paroxysmal Nocturnal HemoglobinuriaEnrolling by invitationNCT07657052Not applicable

  Sponsor listed in the registry: Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.

• Phase II/III Study of FXS5626 in Participants With Non-segmental VitiligoNot yet recruitingNCT07840820Phase 2/3

  Sponsor listed in the registry: Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.

• A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple MyelomaRecruitingNCT07477587Phase 1

  Sponsor listed in the registry: Shanghai Henlius Biotech

• A Phase II Study of HLX22 in Combination With Trastuzumab and Chemotherapy in HER2-Positive Locally Advanced or Metastatic Breast Cancer PatientsNot yet recruitingNCT07824869Phase 2

  Sponsor listed in the registry: Shanghai Henlius Biotech

• A Phase 2 Study of Luvometinib Combined With Anlotinib in KRAS-mutated NSCLCRecruitingNCT07562581Phase 2

  Sponsor listed in the registry: Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.

• A Phase I/II Open-label, Single-arm, Multicenter Clinical Study to Evaluate the Safety and Efficacy of FKC289 in Subjects With Relapsed/Refractory Primary AL AmyloidosisNot yet recruitingNCT07765524Phase 1/2

  Sponsor listed in the registry: Shenzhen Fosun Kairos Biotechnology Co., Ltd. · Shenzhen Fosun Kairos Biotechnology Co., Ltd. — acquired company within the Fosun Pharma group

• A Phase 1 Study of FXR0906 in Healthy Adults With or Without Elevated TriglyceridesNot yet recruitingNCT07766759Phase 1

  Sponsor listed in the registry: Fosun Pharmaceutical Industrial Development (Shenzhen) Co., Ltd.

• A Phase I/II Open-label, Single-arm, Multicenter Clinical Study to Evaluate the Safety and Efficacy of FKC289 in Subjects With Relapsed/Refractory Membranous NephropathyNot yet recruitingNCT07765537Phase 1/2

  Sponsor listed in the registry: Shenzhen Fosun Kairos Biotechnology Co., Ltd. · Shenzhen Fosun Kairos Biotechnology Co., Ltd. — acquired company within the Fosun Pharma group

• A Phase I Clinical Study of HLX3902 in Patients With mCRPC and Other Advanced TumoursRecruitingNCT07533708Phase 1

  Sponsor listed in the registry: Shanghai Henlius Biotech

• FXS6837 for the Treatment for IgAN Patients（Longterm Study）Not yet recruitingNCT07750665Phase 2

  Sponsor listed in the registry: Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.

• A Study of the Efficacy and Safety of FXS6837 Capsules Compared to Eculizumab for 24 Weeks in Patients With PNH.Not yet recruitingNCT07747090Phase 3

  Sponsor listed in the registry: Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.

• A Study of HLX18 vs. OPDIVO® in Multiple Resected Solid TumorsRecruitingNCT07518043Phase 1

  Sponsor listed in the registry: Shanghai Henlius Biotech

• A Phase II Clinical Study to Evaluate HLX43 in Combination With Serplulimab in Subjects With Advanced Lung CancerRecruitingNCT07253142Phase 2

  Sponsor listed in the registry: Shanghai Henlius Biotech

• A Phase I Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of HLX3901 in Patients With Advanced SCLC or NECRecruitingNCT07416695Phase 1

  Sponsor listed in the registry: Shanghai Henlius Biotech

• A Phase I Clinical Study to Evaluate the Safety, Tolerability, and PK of HLX48 in Advanced/Metastatic Solid TumorsRecruitingNCT07473726Phase 1

  Sponsor listed in the registry: Shanghai Henlius Biotech

• A Study of Automated Axicabtagene Ciloleucel for R/R Large B-cell Lymphoma.RecruitingNCT07606937Early Phase 1

  Sponsor listed in the registry: Shenzhen Fosun Kairos Biotechnology Co., Ltd. · Shenzhen Fosun Kairos Biotechnology Co., Ltd. — acquired company within the Fosun Pharma group

• A Phase II Study to Evaluate the Efficacy and Safety of HLX43 + Serplulimab as Neoadjuvant Therapy in Subjects With NSCLCRecruitingNCT07269782Phase 2

  Sponsor listed in the registry: Shanghai Henlius Biotech

• A Global Phase II/III Clinical Study to Evaluate the Efficacy and Safety of HLX43 Monotherapy or HLX43 in Combination With HLX07 Versus Docetaxel in Advanced or Metastatic Squamous Non-Small Cell Lung CancerRecruitingNCT07459751Phase 2/3

  Sponsor listed in the registry: Shanghai Henlius Biotech

• A Phase I Clinical Study of HLX316 in Participants With Advanced/Metastatic Solid TumorsRecruitingNCT07541534Phase 1

  Sponsor listed in the registry: Shanghai Henlius Biotech

• A Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of HLX319 vs. EU-Phesgo® in the Neoadjuvant Therapy of HER2-Positive Early or Locally Advanced Breast CancerNot yet recruitingNCT07601620Phase 1

  Sponsor listed in the registry: Shanghai Henlius Biotech

• A Phase II Clinical Study to Evaluate HLX43 in Patients With Recurrent/Metastatic ESCC Failed or Intolerance to Standard TherapyRecruitingNCT06769113Phase 2

  Sponsor listed in the registry: Shanghai Henlius Biotech

• Phase Ia/Ib Study of FXB0871 Monotherapy in Locally Advanced/Metastatic Solid TumorsNot yet recruitingNCT07558200Phase 1

  Sponsor listed in the registry: Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.

• A Phase I Multicentre Randomized Double-Blind Parallel-Controlled Study of HLX05-N vs. ERBITUX® in Metastatic Colorectal CancerNot yet recruitingNCT07543471Phase 1

  Sponsor listed in the registry: Shanghai Henlius Biotech

• A Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX43 (Anti-PD-L1 ADC) in Patients With Advanced Gynecological Malignant TumorsRecruitingNCT06769152Phase 2

  Sponsor listed in the registry: Shanghai Henlius Biotech

• Pharmacokinetic Characteristics, Safety, and Immunogenicity of HLX319 Compared With EU-Phesgo®Not yet recruitingNCT07495930Phase 1

  Sponsor listed in the registry: Shanghai Henlius Biotech

• FXS6837 for the Treatment of IgAN PatientsNot yet recruitingNCT07502638Phase 2

  Sponsor listed in the registry: Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.

• Phase II Study of HLX43 Monotherapy or Combined With Immune Checkpoint Inhibitors in Patients With Locally Advanced, Recurrent, or Metastatic Triple-negative Breast Cancer.Not yet recruitingNCT07487519Phase 2

  Sponsor listed in the registry: Shanghai Henlius Biotech

• A Study to Evaluate the Safety, PK, and Immunogenicity of Recombinant Human Hyaluronidase in Healthy SubjectsNot yet recruitingNCT07484893Phase 1

  Sponsor listed in the registry: Shanghai Henlius Biotech

• A Study to Evaluate HLX22 in Combination With HLX87 in Patients With HER2-Positive Recurrent or Metastatic Breast CancerRecruitingNCT07294508Phase 2/3

  Sponsor listed in the registry: Shanghai Henlius Biotech

• Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HLX97 (a KAT6A/B Inhibitor) in Patients With Advanced/Metastatic Solid TumorNot yet recruitingNCT07480681Phase 1

  Sponsor listed in the registry: Shanghai Henlius Biotech

• Phase I Clinical Study To Evaluate Pharmacokinetic Profile, Safety, Efficacy and Immunogenicity Of Ipilimumab Biosimilar HLX13 Vs. YERVOY® (US-Sourced YERVOY®) As A First-Line Treatment For Patients With Unresectable Hepatocellular CarcinomaRecruitingNCT07176650Phase 1

  Sponsor listed in the registry: Shanghai Henlius Biotech

• A Phase II Study to Evaluate the Efficacy and Safety of HLX43 in Patients With Hormone Receptor Positive, HER2 Negative Locally Advanced or Metastatic Breast CancerNot yet recruitingNCT07459738Phase 2

  Sponsor listed in the registry: Shanghai Henlius Biotech

• A Phase II Clinical Study to Evaluate HLX43 in Subjects With Recurrent or Metastatic Head and Neck Squamous Cell CarcinomaRecruitingNCT06857279Phase 2

  Sponsor listed in the registry: Shanghai Henlius Biotech

• A Phase I Study to Evaluate the Safety, Tolerability, and PK of HLX37 in Advanced/Metastatic Solid TumorsRecruitingNCT07274813Early Phase 1

  Sponsor listed in the registry: Shanghai Henlius Biotech

• A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric CancerRecruitingNCT06532006Phase 3

  Sponsor listed in the registry: Shanghai Henlius Biotech

• A Phase Ib/II Study to Evaluate HLX43 Combined With HLX07 or Serplulimab in Patients With Advanced or Metastatic Colorectal CancerNot yet recruitingNCT07358585Phase 1/2

  Sponsor listed in the registry: Shanghai Henlius Biotech

• Phase I Study of FXS887 in the Treatment of Solid TumorsNot yet recruitingNCT07345637Phase 1

  Sponsor listed in the registry: Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.

• A Phase II/III Clinical Study to Evaluate HLX07 in Combination With Serplulimab and Chemotherapy Versus Placebo in Combination With Serplulimab or Pembrolizumab and Chemotherapy as First-Line Treatment in Advanced Squamous Non-Small Cell Lung CancerNot yet recruitingNCT07318883Phase 2/3

  Sponsor listed in the registry: Shanghai Henlius Biotech

• A Phase II Clinical Study to Evaluate HLX43 in Subjects With Advanced Pancreatic CancerNot yet recruitingNCT07301229Phase 2

  Sponsor listed in the registry: Shanghai Henlius Biotech